Cat. No. 1278
Chemical Name: N-[2-[[[3-(4-Chlorophenyl)-2-propenyl]methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4-methoxybenzenesulphonamide
Biological ActivityPotent, cell permeable inhibitor of CaM kinase II (IC50 = 0.37 μM). Also a direct extracellular open channel blocker of voltage-gated potassium channels (IC50 = 307 nM for Kv1.5); independent of CaM kinase II inhibition.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Sumi et al (1991) The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine content in PC12h cells. Biochem.Biophys.Res.Comm. 181 968.
Anderson et al (1998) KN-93, an inhibitor of multifunctional Ca2+/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart. J.Pharmacol.Exp.Ther. 287 996. PMID: 9864285.
Patel et al (1999) Calcium/calmodulin-dependent phosphorylation and activation of human Cdc25-C at the G2/M phase transition in HeLa cells. J.Biol.Chem. 274 7958. PMID: 10075693.
Rezazadeh et al (2006) KN-93 (2-[N-(2-Hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]-amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J.Pharmacol.Exp.Ther. 317 292. PMID: 16368898.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: KN-93, supplier, K+, channel, blockers, KV, inhibitors, Potassium, Channels, voltage-gated, voltage-dependent, CaM, Kinase, II, kinases, Calmodulin-Activated, calmodulin-dependent, Protein, Ca2+, Binding, modulators, Calcium, Signaling, Signalling, hERG, Human, Ether-A-Go-Go, Gene, KCNQ
Find multiple products by catalog number
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.